title: Defining and Targeting the Oncogenic Drivers of Neuroendocrine Prostate Cancer.
abstract: In this issue of Cancer Cell, Lee and colleagues (2016) define the biologic role of MYCN in promoting prostate tumorigenesis and development of a neuroendocrine phenotype. This has important implications for the clinical management of neuroendocrine prostate cancer as Aurora A kinase inhibitors promoting N-Myc destabilization progress in the clinic.
authors.affiliation: Department of Surgery, Division of Urology, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA. Electronic address: carverb@mskcc.org.
authors.forename: Brett S
authors.initials: BS
authors.lastname: Carver
mesh_terms: D064096:Aurora Kinase A; D018278:Carcinoma, Neuroendocrine; D045744:Cell Line, Tumor; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000235:genetics*
chemical_list: D064096:Aurora Kinase A